DPA-714 PET/MRI ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03759522 (ClinicalTrials.gov) | February 3, 2019 | 6/11/2018 | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. | Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy | Drug: DPA-714 PET/MRI | University of Alabama at Birmingham | NULL | Recruiting | 18 Years | 65 Years | All | 120 | Phase 1 | United States |